Source-grounded facts extracted from Zoetis Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Louise M. Parent retired as Director at Zoetis Inc..
“Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.”
Zoetis Inc. reported full year 2026 results: revenue $9.680 - $9.960 Billion, EPS $6.85 to $7.00.
“Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion with Organic Operational Revenue Growth of 2% to 5% • Revises Full Year 2026 Guidance for Organic Operational Growth in Adjusted Net Income to 2% to 6% • Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00”
Zoetis Inc. reported Q1 2026 results: revenue $2.3 Billion, net income $601 million, EPS $1.42 per diluted share.
“Zoetis Announces First Quarter 2026 Results • Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis • Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53”
Zoetis Inc. entered into Purchase Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $2.0 billion (effective 2025-12-15).
“The Notes were sold in a private placement under a purchase agreement, dated as of December 15, 2025 (the “Purchase Agreement”), between the Company and Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC as representatives of the several initial purchasers named therein”
Zoetis Inc. entered into Indenture with Deutsche Bank Trust Company Americas valued at $2.0 billion (effective 2025-12-18).
“The Notes were issued pursuant to an indenture, dated as of December 18, 2025 (the “Indenture”), between the Company and Deutsche Bank Trust Company Americas, as trustee.”
Zoetis Inc. issued convertible note to Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC as representatives of the several initial purchasers for $2.0 billion aggregate principal amount.
“buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the Notes sold in the Offering was $2.0 billion, which includes $250 million in aggregate principal amount of Notes issued pursuant to the Initial Purchasers’ option to purchase additional Notes on the same terms and”
Zoetis Inc. incurred convertible notes of $2.0 billion at 0.25% per year maturing June 15, 2029.
“buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the Notes sold in the Offering was $2.0 billion, which includes $250 million in aggregate principal amount of Notes issued pursuant to the Initial Purchasers’ option to purchase additional Notes on the same terms and”
Mark Stetter was elected as director at Zoetis Inc..
“Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.”
Robert Scully retired as director at Zoetis Inc..
“Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc.”
Keith Sarbaugh was appointed as Executive Vice President and Chief Digital & Technology Officer at Zoetis Inc..
“As a result of Ms. Mamilli’s planned departure, Keith Sarbaugh has been promoted to the role of Executive Vice President and Chief Digital & Technology Officer effective immediately.”
Wafaa Mamilli departed as Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis Inc..
“On November 11, 2024, Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, informed Zoetis Inc. (the “Company”) of her decision to leave the Company in early 2025 to pursue an external opportunity.”
Heidi C. Chen departed as EVP, General Counsel at Zoetis Inc..
“On May 20, 2024, in connection with Heidi C. Chen’s previously announced separation, Zoetis Inc. (the “Company”) entered into a Letter Agreement”
Linda Rhodes retired as Director at Zoetis Inc..
“Effective May 21, 2024, Dr. Linda Rhodes retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.”
Zoetis Inc. reported first quarter of 2024 results: revenue $2.2 billion, net income $599 million, EPS $1.31 per diluted share. Guidance raised.
“Exchange Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Announces First Quarter 2024 Results • Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 • Delivers 12%”
Roxanne Lagano was appointed as interim General Counsel and Corporate Secretary at Zoetis Inc..
“Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations, will serve as interim General Counsel and Corporate Secretary while the Company conducts a search for Ms. Chen’s permanent replacement.”
Heidi C. Chen departed as Executive Vice President, General Counsel and Corporate Secretary at Zoetis Inc..
“Effective April 16, 2024, Heidi C. Chen will cease her role as Executive Vice President, General Counsel and Corporate Secretary, and Business Lead of Human Health Diagnostics of Zoetis Inc. (the “Company”).”
Gavin D.K. Hattersley was appointed as Director at Zoetis Inc..
“On April 1, 2024, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Gavin D.K. Hattersley to the Board,”
Zoetis Inc. reported full year 2024 results: revenue $9.075 - $9.225 Billion, EPS $5.34 to $5.44 on a Reported Basis, or $5.74 to $5.84 on an Adjusted Basis. Guidance initiated.
“Provides Full Year 2024 Revenue Guidance of $9.075 - $9.225 Billion, with Diluted EPS of $5.34 to $5.44 on a Reported Basis, or $5.74 to $5.84 on an Adjusted Basis”
Zoetis Inc. reported full year 2023 results: revenue $8.5 Billion, net income $2.3 Billion, EPS $5.07 per Diluted Share. Guidance initiated.
“For Full Year 2023, Zoetis Reports Revenue of $8.5 Billion, Growing 6%, and Net Income of $2.3 Billion, or $5.07 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis”
Zoetis Inc. reported the fourth quarter and full year 2023 results: revenue $2.2 billion, net income $525 million, EPS $1.14 per diluted share. Guidance initiated.
“Zoetis Reports Fourth Quarter and Full Year 2023 Results • For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis”
Zoetis Inc. reported the third quarter of 2023 results: revenue $2.2 Billion, net income $596 Million, EPS $1.29 per Diluted Share. Guidance reaffirmed.
“The company reported revenue of $2.2 billion for the third quarter of 2023, an increase of 7% compared with the third quarter of 2022.”
Zoetis Inc. reported the second quarter of 2023 results: revenue $2.2 Billion, net income $671 million, EPS $1.45 per diluted share.
“Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Announces Second Quarter 2023 Results • Reports Revenue of $2.2 Billion, Growing 6%, and Net Income of $671 Million, or $1.45 per Diluted Share, Increasing 27% and 29%, Respectively, on a Reported Basis for Second Quarter 2023 • Delivers 9%”
Zoetis Inc.: Adopted procedural provisions for calling special shareholder meetings (effective 2023-05-18).
“in connection with the shareholder approval of the Special Meeting Amendment and effective upon the filing of the Restated Certificate on May 18, 2023, the Board made certain amendments to the Company’s Amended and Restated By-laws”
Zoetis Inc.: Created a right for shareholders to call a special meeting (effective 2023-05-18).
“to approve an amendment to the Company’s Restated Certificate of Incorporation”
Zoetis Inc. reported first quarter of 2023 results: revenue $2.0 billion, net income $552 million, or $1.19 per diluted share. Guidance reaffirmed.
“Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $552 Million, or $1.19 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for First Quarter 2023 • Delivers 4% Operational Growth in Revenue and a 3% Operational Decline in Adjusted Net Income for First Quarter 2023 • Reports Adjusted Net Income of $607 Million, or Adjusted Diluted EPS of $1.31, for First Quarter 2023 • Maintains Full Year 2023 Revenue Guidance of $8.575 - $8.725 Billion, with Diluted EPS of $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis”
Zoetis Inc. reported Full Year 2023 results: revenue $8.575 - $8.725 Billion, EPS $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis. Guidance initiated.
“Provides Full Year 2023 Revenue Guidance of $8.575 - $8.725 Billion, with Diluted EPS of $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis”
Zoetis Inc. reported Full Year 2022 results: revenue $8.1 Billion, net income $2.1 Billion, or $4.49 per Diluted Share.
“For Full Year 2022, Zoetis Reports Revenue of $8.1 Billion, Growing 4%, and Net Income of $2.1 Billion, or $4.49 per Diluted Share, on a Reported Basis”
Zoetis Inc. reported the fourth quarter and full year 2022 results: revenue $2.0 Billion, net income $461 Million, or $0.99 per Diluted Share. Guidance initiated.
“specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Reports Fourth Quarter and Full Year 2022 Results • For Fourth Quarter 2022, Zoetis Reports Revenue of $2.0 Billion, Growing 4%, and Net Income of $461 Million, or $0.99 per Diluted Share, on a Reported Basis ◦ Delivers 9% Operational Growth in Revenue and 27% Operational Growth in Adjusted”
William Dorsey was appointed as interim head of U.S. Operations and Global Diagnostics at Zoetis Inc..
“William (“Chip”) Dorsey, Vice President, Finance will serve as interim head of U.S. Operations and Global Diagnostics while the Company conducts a search for Mr. David’s permanent replacement.”
Glenn David was terminated as Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc..
“On February 5, 2023, Zoetis terminated Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc. (the “Company”), for violating company policy by engaging in a consensual personal relationship and failing to disclose it to the Company.”
Zoetis Inc. incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A. (as administrative agent) at adjusted term SOFR rate plus an applicable margin maturing five years from the closing date.
“On December 21, 2022, Zoetis Inc. (the “Company”) entered into a revolving credit agreement (the “Credit Agreement”) with a syndicate of banks, JPMorgan Chase Bank, N.A., as administrative agent, and Barclays Bank PLC, Bank of America, N.A., Citibank, N.A. and MUFG Bank, Ltd., as syndication agents, providing for a five-year $1.0 billion senior unsecured revolving credit facility.”
Zoetis Inc. terminated the Prior Credit Agreement with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (effective 2022-12-21).
“On December 21, 2022, the Company terminated that certain Credit Agreement dated as of December 21, 2016, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, (the “Prior Credit Agreement”) and all commitments to extend further credit thereunder were therefore terminated.”
Zoetis Inc. entered into Credit Agreement with a syndicate of banks, JPMorgan Chase Bank, N.A., as administrative agent, and Barclays Bank PLC, Bank of America, N.A., Citibank, N.A. and MUFG Bank, Ltd., as syndication agents valued at $1.0 billion (effective 2022-12-21).
“On December 21, 2022, Zoetis Inc. (the “Company”) entered into a revolving credit agreement (the “Credit Agreement”) with a syndicate of banks, JPMorgan Chase Bank, N.A., as administrative agent, and Barclays Bank PLC, Bank of America, N.A., Citibank, N.A. and MUFG Bank, Ltd., as syndication agents, providing for a five-year $1.0 billion senior unsecured revolving credit facility.”
Zoetis Inc.: Amended and restated bylaws to enhance procedural mechanics and disclosure requirements for shareholder nominations and update information requirements regarding economic instruments (effective 2022-12-08).
“On December 8, 2022, in connection with the new Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the Amended and Restated By-laws of Zoetis Inc. (the “Company”), the Board of Directors (the “Board”) of the Company adopted and approved an amendment and restatement of the Company’s Amended and Restated By-laws (as amended and restated, the “Amended By-laws”), effective immediately.”
Zoetis Inc. reported third quarter of 2022 results: revenue $2.0 Billion, net income $529 Million, or $1.13 per Diluted Share. Guidance lowered.
“Zoetis Announces Third Quarter 2022 Results • Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $529 Million, or $1.13 per Diluted Share, Decreasing 4% and 3%, Respectively, on a Reported Basis for Third Quarter 2022”
Wafaa Mamilli changed role as Chief Digital and Technology Officer at Zoetis Inc..
“Wafaa Mamilli, the Company’s Chief Digital and Technology Officer, will also assume oversight of China, Brazil and Precision Animal Health, effective November 1, 2022.”
Jamie Brannan was appointed as Executive Vice President and Group President, International Operations and Aquaculture (PHARMAQ) at Zoetis Inc..
“the Company has appointed Jamie Brannan, who currently serves as the Company’s President, International Operations, as the Executive Vice President and Group President, International Operations and Aquaculture (PHARMAQ), effective November 1, 2022.”
Glenn David was appointed as Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc..
“Zoetis Inc. (the “Company”) appointed Glenn David as the Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, effective November 1, 2022.”
Vanessa Broadhurst was appointed as Director at Zoetis Inc..
“On July 25, 2022, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Vanessa Broadhurst to the Board, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal.”
Roman Trawicki departed as Executive Vice President and President, Global Manufacturing and Supply at Zoetis Inc..
“On April 19, 2022, Mr. Roman Trawicki, the Executive Vice President and President, Global Manufacturing and Supply at Zoetis Inc. (the “Company”) provided notice of his intention to retire from the Company.”
Robert J. Polzer was appointed as Executive Vice President and President of Research & Development at Zoetis Inc..
“the Company has appointed Robert J. Polzer, PhD, who currently serves as the Company’s Senior Vice President of Global Therapeutics, to succeed Dr. Knupp as the Company’s Executive Vice President and President of Research & Development, effective January 1, 2022”
Catherine Knupp retired as Executive Vice President and President of Research & Development at Zoetis Inc..
“Dr. Catherine Knupp, DVM, MS, the Company’s Executive Vice President and President of Research & Development, has provided notice of her intention to retire from her position, effective December 31, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.